RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Nanjing Drum Tower Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05661786, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Neutrophil count <2×10\^9/L and/or platelet count <100×10\^9/L;

    Exclusion criterion 10

  3. Pregnant or planned pregnancy in a short term or lactation patients;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05661786, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Hepatitis B surface antigen (HBsAg) positive over 6 months
  • Age ≥18 years
  • Treatment-naïve
  • HBeAg negative, anti-HBe positive
  • HBV DNA >2000 IU/mL
  • Persistently normal alanine transaminase (ALT)
  • Liver inflammation <G2 or A2 and liver fibrosis <S2 or F2 before enrollment, or liver stiffness >8 kilopascals (kPa)
  • No family history of liver cirrhosis or hepatocellular carcinoma

Exclusion Criteria:

  • Coinfection with hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus or human immunodeficiency virus;
  • Coexisting of hepatocellular carcinoma and other malignancy, or alpha-fetoprotein >upper limit of normal at enrollment;
  • Presence of liver cirrhosis;
  • Alcohol abuse within the last year (ethanol: male >40 g/d, female >20 g/d; or heavy drinking within 2 weeks before enrollment: ethanol >80 g/d), or history of drug abuse;
  • Participating in other clinical trials in the last 3 months;
  • Coexisting of autoimmune liver diseases;
  • Pregnant or planned pregnancy in a short term or lactation patients;
  • History of severe heart disease, mental disease;
  • Uncontrolled diabetes, hypertension, thyroid dysfunction, retinopathy, autoimmune diseases;
  • Neutrophil count <2×10\^9/L and/or platelet count <100×10\^9/L;
  • History of organ transplantation or preparing for organ transplantation;
  • Using immunosuppressive drugs;
  • Undergone organ transplantation or preparing for organ transplantation;
  • Receiving immunosuppressive agents;
  • Patients thought by the investigators not suitable to participate in this study.

Quoted from ClinicalTrials.gov, NCT05661786, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05661786, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05661786